Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

RJ. Motzer, TE. Hutson, H. Glen, MD. Michaelson, A. Molina, T. Eisen, J. Jassem, J. Zolnierek, JP. Maroto, B. Mellado, B. Melichar, J. Tomasek, A. Kremer, HJ. Kim, K. Wood, C. Dutcus, J. Larkin,

. 2015 ; 16 (15) : 1473-82. [pub] 20151022

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16009926
E-zdroje Online Plný text

NLK ProQuest Central od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci

Odkazy

PubMed 26482279
DOI 10.1016/s1470-2045(15)00290-9
Knihovny.cz E-zdroje

BACKGROUND: Currently, metastatic renal cell carcinoma is treated with sequential single agents targeting VEGF or mTOR. Here, we aimed to assess lenvatinib, everolimus, or their combination as second-line treatment in patients with metastatic renal cell carcinoma. METHODS: We did a randomised, phase 2, open-label, multicentre trial at 37 centres in five countries and enrolled patients with advanced or metastatic, clear-cell, renal cell carcinoma. We included patients who had received treatment with a VEGF-targeted therapy and progressed on or within 9 months of stopping that agent. Patients were randomised via an interactive voice response system in a 1:1:1 ratio to either lenvatinib (24 mg/day), everolimus (10 mg/day), or lenvatinib plus everolimus (18 mg/day and 5 mg/day, respectively) administered orally in continuous 28-day cycles until disease progression or unacceptable toxic effects. The randomisation procedure dynamically minimised imbalances between treatment groups for the stratification factors haemoglobin and corrected serum calcium. The primary objective was progression-free survival in the intention-to-treat population. This study is closed to enrolment but patients' treatment and follow-up is ongoing. This study is registered with ClinicalTrials.gov, number NCT01136733. FINDINGS: Between March 16, 2012, and June 19, 2013, 153 patients were randomly allocated to receive either the combination of lenvatinib plus everolimus (n=51), single-agent lenvatinib (n=52), or single-agent everolimus (n=50). Lenvatinib plus everolimus significantly prolonged progression-free survival compared with everolimus alone (median 14·6 months [95% CI 5·9-20·1] vs 5·5 months [3·5-7·1]; hazard ratio [HR] 0·40, 95% CI 0·24-0·68; p=0·0005), but not compared with lenvatinib alone (7·4 months [95% CI 5·6-10·2]; HR 0·66, 95% CI 0·30-1·10; p=0·12). Single-agent lenvatinib significantly prolonged progression-free survival compared with everolimus alone (HR 0·61, 95% CI 0·38-0·98; p=0·048). Grade 3 and 4 events occurred in fewer patients allocated single-agent everolimus (25 [50%]) compared with those assigned lenvatinib alone (41 [79%]) or lenvatinib plus everolimus (36 [71%]). The most common grade 3 or 4 treatment-emergent adverse event in patients allocated lenvatinib plus everolimus was diarrhoea (ten [20%]), in those assigned single-agent lenvatinib it was proteinuria (ten [19%]), and in those assigned single-agent everolimus it was anaemia (six [12%]). Two deaths were deemed related to study drug, one cerebral haemorrhage in the lenvatinib plus everolimus group and one myocardial infarction with single-agent lenvatinib. INTERPRETATION: Lenvatinib plus everolimus and lenvatinib alone resulted in a progression-free survival benefit for patients with metastatic renal cell carcinoma who have progressed after one previous VEGF-targeted therapy. Further study of lenvatinib is warranted in patients with metastatic renal cell carcinoma. FUNDING: Eisai Inc.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16009926
003      
CZ-PrNML
005      
20160418121545.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(15)00290-9 $2 doi
024    7_
$a 10.1016/S1470-2045(15)00290-9 $2 doi
035    __
$a (PubMed)26482279
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Motzer, Robert J $u Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org.
245    10
$a Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial / $c RJ. Motzer, TE. Hutson, H. Glen, MD. Michaelson, A. Molina, T. Eisen, J. Jassem, J. Zolnierek, JP. Maroto, B. Mellado, B. Melichar, J. Tomasek, A. Kremer, HJ. Kim, K. Wood, C. Dutcus, J. Larkin,
520    9_
$a BACKGROUND: Currently, metastatic renal cell carcinoma is treated with sequential single agents targeting VEGF or mTOR. Here, we aimed to assess lenvatinib, everolimus, or their combination as second-line treatment in patients with metastatic renal cell carcinoma. METHODS: We did a randomised, phase 2, open-label, multicentre trial at 37 centres in five countries and enrolled patients with advanced or metastatic, clear-cell, renal cell carcinoma. We included patients who had received treatment with a VEGF-targeted therapy and progressed on or within 9 months of stopping that agent. Patients were randomised via an interactive voice response system in a 1:1:1 ratio to either lenvatinib (24 mg/day), everolimus (10 mg/day), or lenvatinib plus everolimus (18 mg/day and 5 mg/day, respectively) administered orally in continuous 28-day cycles until disease progression or unacceptable toxic effects. The randomisation procedure dynamically minimised imbalances between treatment groups for the stratification factors haemoglobin and corrected serum calcium. The primary objective was progression-free survival in the intention-to-treat population. This study is closed to enrolment but patients' treatment and follow-up is ongoing. This study is registered with ClinicalTrials.gov, number NCT01136733. FINDINGS: Between March 16, 2012, and June 19, 2013, 153 patients were randomly allocated to receive either the combination of lenvatinib plus everolimus (n=51), single-agent lenvatinib (n=52), or single-agent everolimus (n=50). Lenvatinib plus everolimus significantly prolonged progression-free survival compared with everolimus alone (median 14·6 months [95% CI 5·9-20·1] vs 5·5 months [3·5-7·1]; hazard ratio [HR] 0·40, 95% CI 0·24-0·68; p=0·0005), but not compared with lenvatinib alone (7·4 months [95% CI 5·6-10·2]; HR 0·66, 95% CI 0·30-1·10; p=0·12). Single-agent lenvatinib significantly prolonged progression-free survival compared with everolimus alone (HR 0·61, 95% CI 0·38-0·98; p=0·048). Grade 3 and 4 events occurred in fewer patients allocated single-agent everolimus (25 [50%]) compared with those assigned lenvatinib alone (41 [79%]) or lenvatinib plus everolimus (36 [71%]). The most common grade 3 or 4 treatment-emergent adverse event in patients allocated lenvatinib plus everolimus was diarrhoea (ten [20%]), in those assigned single-agent lenvatinib it was proteinuria (ten [19%]), and in those assigned single-agent everolimus it was anaemia (six [12%]). Two deaths were deemed related to study drug, one cerebral haemorrhage in the lenvatinib plus everolimus group and one myocardial infarction with single-agent lenvatinib. INTERPRETATION: Lenvatinib plus everolimus and lenvatinib alone resulted in a progression-free survival benefit for patients with metastatic renal cell carcinoma who have progressed after one previous VEGF-targeted therapy. Further study of lenvatinib is warranted in patients with metastatic renal cell carcinoma. FUNDING: Eisai Inc.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protinádorové látky $x aplikace a dávkování $7 D000970
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x sekundární $7 D002292
650    _2
$a everolimus $x aplikace a dávkování $7 D000068338
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x patologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a fenylmočovinové sloučeniny $x aplikace a dávkování $7 D010671
650    _2
$a chinoliny $x aplikace a dávkování $7 D011804
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hutson, Thomas E $u Texas Oncology, Dallas, TX, USA.
700    1_
$a Glen, Hilary $u Beatson West of Scotland Cancer Centre, Glasgow, UK.
700    1_
$a Michaelson, M Dror $u Massachusetts General Hospital Cancer Center, Boston, MA, USA.
700    1_
$a Molina, Ana $u Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA.
700    1_
$a Eisen, Timothy $u Addenbrooke's Hospital, Cambridge Biomedical Research Centre, Cambridge, UK.
700    1_
$a Jassem, Jacek $u Medical University of Gdańsk, Gdańsk, Poland.
700    1_
$a Zolnierek, Jakub $u Centrum Onkologii, Instytut w Warszawie, Warsaw, Poland.
700    1_
$a Maroto, Jose Pablo $u Departamento de Oncología Médica, Barcelona, Spain.
700    1_
$a Mellado, Begoña $u Medical Oncology Department, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain.
700    1_
$a Melichar, Bohuslav $u Onkologicka klinika, Lekarska fakulta Univerzity Palackeho a Fakultni nemocnice, Olomouc, Czech Republic.
700    1_
$a Tomasek, Jiri $u Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic.
700    1_
$a Kremer, Alton $u Eisai Inc, Woodcliff Lake, NJ, USA.
700    1_
$a Kim, Han-Joo $u Eisai Inc, Woodcliff Lake, NJ, USA.
700    1_
$a Wood, Karen $u Eisai Ltd, Hatfield, UK.
700    1_
$a Dutcus, Corina $u Eisai Inc, Woodcliff Lake, NJ, USA.
700    1_
$a Larkin, James $u Royal Marsden Hospital NHS Foundation Trust, London, UK.
773    0_
$w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 16, č. 15 (2015), s. 1473-82
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26482279 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160418121632 $b ABA008
999    __
$a ok $b bmc $g 1113355 $s 934294
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 16 $c 15 $d 1473-82 $e 20151022 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace